Vertex Pharmaceuticals Investor Presentation — May 2022

Document content

©2022 Vertex Pharmaceuticals Incorporated 12AGENDA

Michael Partridge, Senior Vice President, Investor Relations

CEO Perspective and Pipeline Update

Reshma Kewalramani, M.D., Chief Executive Officer and President

Stuart Arbuckle, Executive Vice President and Chief Operating Officer

Charlie Wagner, Executive Vice President and Chief Financial Officer3SAFE HARBOR STATEMENT & NON- GAAP FINANCIAL MEASURES

This presentation contains forward -looking statements as defined in the Private Securities Litigation Reform Act of 1995, as ame nded, including, without limitation, the information provided regarding future

financial performance and operations, the section captioned "Full -Year 2022 Financial Guidance", and statements regarding ( i) the expectations, development plans, anticipated timelines for and potential

benefits of the company’s products and product candidates, including study designs, clinical site initiations, patient enroll men t, data availability, anticipated regulatory filings, approvals, and timing thereof, (ii)

expectations for continued growth in the number of CF patients treated with our products, including reaching all CF patients who can benefit from our marketed products, expansion of treatment options for the

patients who do not benefit from CFTR modulators and anticipated size of patient populations, (iii) our plans to treat addition al CF patients with mRNA, including plans for a CFTR mRNA IND filing in 2022, (iv)

expectations for our next- in-class, once -daily triple regimen for CF patients, including our Phase 3 program expectations, enrol lment plans and related economics, (v) our plans regarding Phase 2/3 study of VX -147

in AMKD, and our beliefs regarding anticipated results of the study and the possibility for accelerated approval in the U.S., (vi) expectations for the CTX001 program, including the potential of CTX001 to be a

curative approach for patients with TDT and SCD, expectations for program approval and launch, and potential commercial oppor tunity, (vi) expectations regarding the potential benefits of our pain program and

products, and plans for the advancement of VX -548 into pivotal development in acute pain in the second half of 2022 (vii) expectations for uptake of and expanded access to the company’s products, including

additional reimbursement agreements, label expansions and approvals in new markets, (viii) the potential benefits and safety of VX-880, our plans and expectations regarding our Phase 1/2 program for VX -880,

and our plans to continue to progress the Phase 1/2 program for VX -880, (ix) beliefs about delivering treatments and potential c ures for more patients in multiple new disease areas, including potential